-
Ionomycin Calcium Salt in Cancer Assay Design
2026-09-27
Ionomycin calcium salt is a calcium ionophore for controlled studies of intracellular Ca2+ and cell fate. This article explains how to use calcium perturbation as a carefully bounded, orthogonal assay variable alongside cancer-response studies—without confusing it with evidence for DNA-repair targeting.
-
Indometacin Sodium: Applied Assay Workflows
2026-09-26
Build more informative inflammation and remyelination experiments with Indometacin Sodium by matching dose, model, and readout to its multiple biological actions. A practical workflow pairs reported concentration ranges with vehicle controls, orthogonal endpoints, and careful interpretation of drug-related phenotypes.
-
FK866 (APO866) Workflows for Cancer Research
2026-09-25
Use FK866 (APO866) to test how NAMPT-dependent NAD depletion affects cancer-cell survival, with practical workflows for dose finding, metabolic readouts, and cell-death profiling. The approach also offers a careful way to investigate NAD-related resistance hypotheses raised by ovarian cancer research—without treating findings from one cancer model as proof in another.
-
Thymoquinone Protects Against Doxorubicin Cardiotoxicity
2026-09-25
A mouse study reports that thymoquinone attenuated doxorubicin-associated cardiac dysfunction and oxidative injury, with findings consistent with reduced ferroptosis and engagement of Nrf2/HO-1 signaling. Its dose groups and cardiac, biochemical, and tissue readouts offer a useful preclinical framework, while the results remain mechanistic evidence from an animal model rather than proof of clinical benefit.
-
GI 254023X: Practical ADAM10 Inhibitor Workflows
2026-09-24
GI 254023X pairs nanomolar ADAM10 potency with selectivity over ADAM17, making it useful for focused studies of protein shedding, Notch1 signaling, and endothelial barrier injury. This guide turns those use-cases into controlled cell-assay workflows, with troubleshooting advice and a clear distinction between established product findings and questions researchers still need to test.
-
ECL Chemiluminescent Substrate Detection Kit
2026-09-24
Learn how to use ECL Chemiluminescent Substrate Detection Kit (Hypersensitive), SKU K1231, to support western blot chemiluminescent detection of low-abundance proteins. This scenario-based guide distinguishes cell phenotype assays from protein detection and covers membrane compatibility, signal timing, and practical product-selection considerations.
-
Thrombin B-Chain Fragment: Identity and Research Use
2026-09-23
Thrombin is a trypsin-like serine protease with central roles in fibrin formation and platelet signaling. A1057 is a sequence-defined 17-residue thrombin B-chain fragment, so it should not be treated as intact, catalytically active thrombin.
-
MALAT1–miR-125b–STAT3 Axis in Sepsis PCT
2026-09-23
The reference study identifies a MALAT1–miR-125b–STAT3 regulatory circuit that increases procalcitonin expression in sepsis-related inflammatory models. Its combination of clinical samples, U937-cell experiments, fluorescence in situ hybridization, RNA interaction assays, and rescue experiments provides a mechanistic framework for interpreting PCT regulation, while leaving clinical validation and causal translation as important next steps.
-
Aβ42: From Ion Channels to AD Translation
2026-09-22
A mechanistic and translational guide to using Amyloid β-Peptide (1-42) in Alzheimer’s disease research, connecting aggregation state, neuronal ion channel modulation, neurotoxicity assays, and evidence from olive biophenol studies.
-
Ceruletide Workflows for Pancreatic Research
2026-09-22
Ceruletide, also called Caerulein in related literature, connects receptor stimulation with measurable pancreatic secretion, fibrosis, and gastrointestinal motility phenotypes. This workflow guide translates a recent ORM2–ZG16 fibrosis study into practical assay design, formulation controls, and troubleshooting decisions.
-
DREADDs and the Evolution of CNO-Activated GPCRs
2026-09-21
Armbruster and colleagues used directed molecular evolution to create muscarinic GPCRs activated by Clozapine N-oxide rather than acetylcholine. The study established DREADDs as experimentally validated receptors for separating receptor-specific and G-protein-coupled signaling in engineered cells and neurons.
-
A 83-01: ALK-5 Inhibitor for Organoids
2026-09-21
A 83-01 provides reversible control of TGF-β/Smad signaling for organoid, EMT, and growth-response experiments. This guide connects its defined pharmacology with patient-derived breast organoid workflows, emphasizing dose design, assay controls, and troubleshooting.
-
Intermedin, NAMPT/PARP1, and Vascular Senescence
2026-09-20
The 2025 reference study identifies intermedin as a protective regulator of angiotensin II–associated vascular smooth muscle cell senescence in mice. Its central mechanistic finding is that intermedin increases NAD+ through NAMPT and supports PARP1-associated DNA damage responses, offering a framework for understanding vascular aging without equating NAMPT activation with the inhibitory strategies used in oncology.
-
Protoporphyrin IX for Ferroptosis Workflows
2026-09-19
Protoporphyrin IX connects heme-pathway biology with light-triggered oxidative assays and exploratory ferroptosis research. This practical guide explains fresh-use handling, dark-versus-light controls, HCC assay design, and troubleshooting for insoluble photodynamic compounds.
-
Piroxicam and Deracoxib in Canine Mammary Cancer
2026-09-18
The 2012 reference study examined how piroxicam and deracoxib, alone and in combination, affect the canine mammary carcinoma cell line CMT-U27. Its main contribution was linking stronger combination-associated loss of viability with apoptosis and G0/G1 cell-cycle accumulation, while also clarifying that the evidence remains an in vitro pharmacology result rather than a validated clinical treatment.